The effect of monoclonal antibodies (MoAbs) recognizing idiotype, IgM heavy chain, and IgD heavy chain on the in vitro DNA synthesis of five randomly selected leukemic human low-malignancy B-cell lymphomas was investigated. In three lymphomas of different histologic subtype, low concentrations of anti-idiotypic (anti-Id) MoAb completely inhibited spontaneous 'H-thymidine uptake of T-cell-and monocytedepleted tumor cells, whereas two other tumors were not affected. Maximal inhibition of DNA synthesis was achieved at MoAb concentrations ranging from 0.5 to 250 pg/mL and required crosslinking by bivalent antibody but not Fcmediated effects. While two anti-lgM MoAbs were similarly efficient as anti-Id MoAb in inhibition of DNA synthesis, two anti-lgD MoAbs had no effect. Thus, surface IgD molecules seemed to be neither able to deliver inhibitory signals In contrary, splenic and liver B cells from neonatal or very young mice are rendered unresponsive to antigen by pretreatment with anti-Ig antibodies or antigen.4 The inhibition of antigen-induced growth and Ig secretion has been considered an in vitro equivalent to B-cell tolerance? Only membrane IgM, but not IgD, seems to deliver tolerizing signals to immature B cells! Similar to immature normal B cells, the growth of some murine lymphomas is inhibited by surface Ig crosslinking so that these tumors have been considered as models of B-cell toleran~e.'.~
R function of membrane-bound Ig that serves as the antigen receptor for mature as well as immature B cells. In murine and human resting mature B cells, crosslinking of surface IgM and IgD induces activation, as indicated by RNA synthesis, size enlargement, and induction of major histocompatibility complex (MHC) class I1 antigen expression.',' In addition, membrane Ig ligation alone or in combination with soluble factors may induce proliferation. ' . ' In contrary, splenic and liver B cells from neonatal or very young mice are rendered unresponsive to antigen by pretreatment with anti-Ig antibodies or antigen. 4 The inhibition of antigen-induced growth and Ig secretion has been considered an in vitro equivalent to B-cell tolerance? Only membrane IgM, but not IgD, seems to deliver tolerizing signals to immature B cells! Similar to immature normal B cells, the growth of some murine lymphomas is inhibited by surface Ig crosslinking so that these tumors have been considered as models of B-cell toleran~e.'.~
In malignant human B-cell populations, both proliferati~e'.'~ and inhibitory" signaling via the antigen receptor have been reported. Among the chronic lymphocytic leukemia (CLL) tumors that have been studied extensively, most were described to synthesize DNA upon stimulation either with anti-IgM alone or in combination with a variety of lymphokines or growth factor^.^." However, in one case of CLL and two of hairy cell leukemia, growth inhibition by surface Ig crosslinking was ob~erved.~'.'~ Such tumors, exhibiting the phenotype of immature B cells, may serve as models of B-cell tolerance in humans.
Besides their signaling function, Ig receptors determine the specificity of B-cell antibody secretion by displaying an enormous degree of diversity in the antigen-combining site. B-cell tumors, usually exhibiting a monoclonal idiotype, thus possess a highly individual surface marker that can be used for targeting therapeutic reagents. Monoclonal antibodies (MoAbs) recognizing idiotypic determinants on human B-cell lymphomas have been used for therapeutic purposes in more than 28 patients.14 Prolonged infusion of high doses of anti-idiotype (anti-Id) antibodies alone or in combination with a-interferon (a-IFN) was reported to result in partial or complete responses in 60% of the patients. The mechanism of these responses, however, could not yet be e1~cidated.l~
We report here that MoAbs recognizing idiotypic determinants drastically inhibit in vitro spontaneous DNA synthesis in three low-or intermediate-malignancy human B-cell lymphomas of different histologic subtypes. In two of these tumors, suppression of spontaneous tumor cell DNA synthesis persisted when MoAbs were removed after incubation for 48 hours or more. These results indicate that, in anti-Id therapy for B-cell lymphoma, inhibitory signaling via surface Ig may contribute to tumor regression.
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cell (WBC) count of 25,000/pL in patient AS and between 80,000 and 400,OOO/kL in the other patients. With the exception of patient AS, peripheral blood lymphocytes (PBL) from all patients contained more than 97% lymphoma cells as determined by a flow cytometric analysis (see below) of pan-B-cell antigen expression. Tumor cells were obtained by leukapheresis and by Ficoll density gradient purification of mononuclear cells from heparinized blood samples. Cell material was obtained in a clinical trial of antiidiotype therapy for which an informed written consent had been obtained. Tumor PB mononuclear cells (PBMCs) were either used directly or stored in liquid nitrogen until use.
For selected assays, highly purified B cells were obtained from PBMC using a modification of the methods described by Thiele and Lipsky.I7 Before this purification, PBMC from patients PH, LH, TR, and MZ contained 1% to 1.5% cells expressing the T-cell antigens CD2 and CD3 and less than 1% staining for the myelomonocytic antigen CD14, as assessed by a flow cytometric analysis (see below). PBMC from patient AS contained 10% T cells and 7% cells belonging to the myelomonocytic lineage. For depletion of contaminating cells, PBMC were first treated with L-leucine methyl ester, a lysosomotropic agent known to kill human monocytes, natural killer (NK) cells, and, in part, CD8' T cells.17 Briefly, PBMC were suspended in serum-free RPMI 1640 medium (GIBCO, Karlsruhe, Germany) at 5 X 106/mL in the presence of 5 x lo-' mol/L L-leucine methyl ester (Sigma, Munich, Germany). Cells were incubated for 45 minutes at room temperature, washed in complete medium, and rosetted twice with sheep red blood cells (Behring, Marburg, Germany) treated with amino ethylisothiouroniumbromide hydrobromide (AET Sigma). Cells not forming rosettes in the second cycle were considered as virtually pure B cells and were used for proliferation assays. When these cells were analyzed for contaminating non-B cells by flow cytometry, no T cells, myelomonocytic cells, or NK cells were detectable. In addition, highly purified cells did not synthesize DNA upon stimulation with 1 p,g/mL phytohemagglutinin (PHA; Wellcome, Hannover, Germany) so that T cells seemed completely eliminated.
Proliferation assays were performed in RPMI 1640 medium supplemented with 5 x lo-' mol/L mercaptoethanol, nonessential amino acids, 1 mmol/L sodium pyruvate, 2 mmol/L L-glutamine (all supplements from GIBCO), and fetal calf serum (FCS; Seromed, Berlin, Germany) or pooled heatinactivated normal human serum. Serum concentration and sources were adjusted to the requirements of the individual tumor clones (see Results section). Tumor PBMCs were suspended at 2 x 106/mL in complete medium and seeded into 96-well flat-bottom polystyrene tissue culture plates (Costar, Cambridge, MA). Unless indicated otherwise, tumor cells were cultured for a total period of 5 to 7 days. All experiments were set up in triplicates. Sixteen hours before the scheduled end point of the experiment, 1 $ 3 of ['HI-thymidine (5 Ci/mmol; Amersham, Braunschweig, Germany) was added per well. Plates were harvested onto glass fiber filters using a Skatron cell harvester (LKB, Freiburg, Germany) and incorporated radioactivity was measured with a liquid scintillation counter.
Anti-idiotypic, anti-IgM, and anti-IgD heavy chain MoAbs were generated as previously described." Briefly, patients' tumor cells were fused with K6H6B5 (a gift from Dr K. Thielemanns, Brussels), a non-Ig-secreting mouse-human heteromyeloma. The resulting hybridomas were screened for the secretion of human Ig with the isotype displayed by the tumor cells. Usually all hybridomas secreting Ig produced Ig of the correct isotype, suggesting that Ig secretors were all derived from a fusion between tumor cells and K6H6B5 hybridomas. Monoclonal human Ig was purified by immunoaffinity chromatography using goat The following MoAbs were selected as anti-idiotypic and antiheavy chain reagents (isotypes indicated in brackets): APH266 (IgG1) for PH tumor idiotype, AAS125 (IgG1) and AAS108 (IgG2b) for AS idiotype, ALH149 (IgG1) for LH idiotype, ATR187 (IgG1) for TR idiotype, and AMZl (IgG1) for MZ idiotype; NMZ88 (IgG1) and NMZ8 (IgG2b) for k heavy chain, HD9 (IgG2b) for 6 heavy chain. MoAbs NMZ88 and NMZ8 recognized different epitopes on p heavy chain, as detected by a competitive radioimmunoassay on cells. For mass production of MoAbs, hybridoma cells were injected IP into pristane primed BALB/c mice. MoAbs were purified from ascitic fluid by chromatography using diethyl aminoethyl (DEAE)-Affi Gel Blue (Biorad, Munich, Germany).
F(ab'), and Fab' fragments of MoAbs with IgGl isotype were produced using the methods described by Parham.,, MoAbs were adjusted to 2 mg/mL in 0.1 mol/L sodium citrate buffer (pH 3.5) and digested with 35 pg/mL pepsin (Sigma) at 37°C for 1 to 3 hours. The reaction was stopped by the addition of 1/10 volume of 1 mol/L Tris buffer (pH 8.5).
Undigested Ig was removed by ion exchange fast protein liquid chromatography (FPLC) over a MonoQ column (Pharmacia). Resulting F(ab')2 fragments were further processed by reduction with 10 mmol/L L-cysteine for 30 minutes at 37°C. After acetylation with 20 mmol/L iodoacetamide, bivalent and monovalent fragments were separated by gel filtration over a Superose 12 column (Pharmacia). In silver-stained 8.75% polyacrylamide SDS gels, the molecular weight of unreduced complete MoAbs was about 150 Kd, while F(ab'), fragments were found at about 120 Kd and monovalent fragments at about 50 Kd. The purity of the MoAb preparations was greater than 98%.
Cell surface Ig density was quantified by Scatchard plot analy~is.2~ Briefly, 100 p.g of anti-IgM MoAb NMZ88 was labeled with 1 mCi of ['ZSI]iodide (Amersham) by the chloramine T method. Triplicate samples of 1 x lo6 viable tumor cells in FCS-medium with 0.1% NaN, were incubated for 60 minutes at room temperature with increasing amounts of lxI-labeled MoAb (10' to 3 x io7 cpm). The number of cell surface Ig molecules and the avidity of MoAb was calculated assuming a one-site binding model.
For all dilutions and washings in the staining for flow cytometric analysis, RPMI medium containing 2% FCS and 0.1% NaN, was used. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Indirect cytoxiciy assay and determination of cell viability.
RESULTS

Requirements for lymphoma cell DNA synthesis in vitro.
Five low-or intermediate-malignancy B-cell lymphomas were tested for cell density and serum conditions required for in vitro DNA synthesis. Two of these, plasmocytoid lymphomas AS and TR, exhibited a very low rate of unstimulated DNA synthesis under all of the conditions tested (data not shown). Spontaneous 3H-thymidine incorporation of tumors PH and MZ was critically dependent on cell densities of 2 x lo6 cells/mL or higher. DNA synthesis of centrocytic lymphoma PH was best supported by incubation in 10% human serum. DNA synthesis of MZ CLL cells was dependent on mitogenic effects of 15% FCS. LH tumor cells showed the highest rate of spontaneous DNA synthesis even when cultured with 5% human or fetal serum and at 5 x lo5 cells/mL. In all lymphomas, the rate of DNA synthesis varied with the serum batch used and between different time points at which cells had been obtained, and fresh tumor cells showed a higher proliferation than thawed cells.
Anti-idiotypic MoAbs inhibit spontaneous lj"homa cell DNA synthesis in vitro. MoAbs recognizing idiotypic determinants on individual tumors were raised by immunization with purified soluble tumor Ig. MoAbs were considered to be anti-idiotypic if they bound to tumor cells and soluble Ig derived from the autologous lymphoma, but not to control lymphoma cells and Igs of the same isotype and to a panel of tonsillar B cells from different healthy donors (data not shown). With the exception of MoAb AAS108 (isotype IgG2b), all anti-idiotypic MoAbs used in this study were of IgGl isotype.
Patient PBMCs contained low amounts of contaminating T cells and monocytes (17% in patient AS, about 2% in other patients). To rule out indirect effects of anti-Id MoAb on contaminating cells, we used highly purified B cells for the proliferation assays. These cells contained no detectable contamination with T cells, monocytes, and NK cells and, in contrast to unpurified PBMCs, did not proliferate in response to the T-cell mitogen PHA.
Interestingly, proliferation of highly purified PH and LH lymphoma cells was significantly inhibited by PHA (Table  1) . This effect could be due to an "abortive activation" of these tumor cells by the mitogen, which has been described in B cells treated with other mitogen^.'^ When highly purified tumor cells were cultured in the presence of 1 kg/mL anti-Id MoAb, the DNA synthesis of PH, LH, and MZ tumor cells was strongly inhibited, while AS and TR cells were not affected (Table 1) . Control anti-HLA-DR MoAb ISCR3 had no effect on the 3H-thymidine incorporation of purified tumor cells.
The data in Table 1 represent maximum 'H-thymidine incorporation observed with lymphomas AS and TR. The absolute level of DNA synthesis by LH, PH, and MZ tumor cells exhibited considerable variation between individual experiments, depending on the batch of FCS used, the day of blood collection from the patients, and, especially, whether fresh or thawed cells were used. Spontaneous 3H-thymidine incorporation by thawed cells was significantly decreased after treatment with L-leucin methyl ester and rosetting. Data shown for lymphomas LH, PH, and MZ in Table 1 represent an average level of DNA synthesis observed with these tumor cells, as judged from at least five separate experiments. Due to the variation of background DNA synthesis, subsequent experiments were all performed at least three times.
Tumors susceptible and resistant to anti-Id MoAb-mediated inhibition do not differ in phenotype. Morphologic diagnosis and cell surface antigen expression of the lymphomas was 
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compared to detect features correlating with sensitivity or resistance to anti-Id-mediated inhibition of DNA synthesis. Four of five tumors belonged to the subgroup of small lymphocytic lymphomas, with one CLL and three immunocytomas. Among these four, two were susceptible and two were resistant to inhibition (Table 2 ). In addition, a single centrocytic lymphoma in the study was sensitive.
To test whether the number of cell surface Ig molecules correlated with inhibition by anti-Id, a Scatchard analysis was performed using a '251-labeled MoAb recognizing A heavy chain. All tumors expressed surface Ig of IgM isotype ( Table 3 ). Both tumors with high amounts of surface Ig and one of three lymphomas with low Ig density were sensitive to inhibition (Table 2) . Therefore, neither morphology nor membrane IgM density correlated with inhibitory effects of anti-Id.
In a flow cytometric analysis, all tumors stained with MoAb to pan-B-cell antigens CD19, CD20 and HLA-DR (Table 3 ). Tumors with low surface Ig density expressed a number of further B-restricted antigens (CD21, CD23, and CD24) and, in the case of AS and MZ, the CD5 antigen associated with CLL.26 In addition, both in susceptible and resistant tumors, IgD expression was found equivalent to (AS, LH, and MZ) or below (PH and TR) IgM surface expression.
MoAbs to IgM but not to IgD inhibit lymphoma DNA synthesis. Because IgM and IgD molecules on B-cell lymphomas express the same idiotype?' anti-Id MoAbs may exert their inhibitory effect via surface Ig of one or both isotypes. We therefore investigated the effects of two MoAbs recognizing distinct epitopes (data not shown) on )I heavy chain and two MoAbs binding to 6 heavy chain. Before the assays, these MoAbs were shown to bind to surface Ig on lymphomas PH, LH, and MZ in a flow cytometric analysis (Table 3) . Among the MoAbs recognizing p chain, MoAb NMZ88 bound more strongly than NMZ8. Figure 1 shows that in all inhibitable lymphomas, MoAb to IgM but not to IgD could substitute for anti-Id MoAb. The inhibitory potency of anti-IgM MoAb was slightly (LH and MZ) to considerably (PH) lower than that of anti-Id MoAb. Corresponding to a weaker staining in FACS analysis, inhibition by NMZ8 was weaker than by NMZ88.
Because anti-IgM MoAbs have been reported to elicit mitogenic effects at higher concentrations,'' a doseresponse curye of anti-Id and anti-IgM MoAbs was performed. Optimal inhibition by anti-Id MoAb was achieved The lymphomas were classified according to the Kiel nomenclature, based on the histochemical studies of lymph node biopsies. IgM molecules on the surface of lymphoma cells were quantified by Scatchard analysis of '261-labeled MoAb NMZ88 (anti-lgM) binding. at a concentration of 0.5 to 2 pg/mL. Both anti-Id and anti-IgM MoAbs were still inhibitory at concentrations as high as 250 pg/mL (Fig 1) .
Anti-IgD MoAbs HD9 and J A l l did not affect the DNA synthesis by lymphomas at concentrations less than 50 pg/mL (Fig 1) . The lack of inhibition by anti-IgD MoAb could not be due to a lack of binding to the lymphoma cells because clear surface staining was achieved with both MoAbs used for the proliferation assays (Table 3) . At higher concentrations of anti-IgD MoAb HD9, DNA synthesis in tumors PH and MZ was affected to a maximum of 40% inhibition at 250 pg/mL. When a threefold excess of an isotype-matched control anti-Id MoAb (AAS108, IgG2b) was added to the cultures to block Fc receptors on tumor cells, the effect of high concentrations of HD9 was abolished (data not shown). Therefore, the observed inhibition may have been caused by a physical crosslinking of surface IgD with receptors for Fc, a well-known phenomenon that requires ligation of both proteins by the same antibody consequence of direct tumor cell killing. In a short-term cytotoxicity assay with baby rabbit or autologous human serum as a source of complement, no decrease of tumor cell viability was detected (data not shown). This result was not unexpected because all of the anti-Id MoAbs were of IgGl isotype, which does not bind complement. Therefore, tumor cells were incubated for 10 days in the presence or absence of anti-Id MoAb and cell number and viability were determined in 3-day intervals during this period. Data shown in Fig 3 are representative for three independent experiments. Consistently, the pattern of cell survival was unique to each tumor. When incubated in medium alone, PH, LH, and MZ tumor cells showed a viability of 80% or better at all time points. In the presence of anti-Id MoAb, however, the viability of PH and LH tumor cells was markedly decreased. Impairment of tumor cell viability was first detectable on day 4 (PH) or 6 (Fig 4) . For tumor PH, 4 hours of incubation was sufficient to completely inhibit further spontaneous 'H-thymidine incorporation. In contrast, MZ cells showed an equal or even considerably higher rate of DNA synthesis after anti-Id MoAb was withdrawn. Thus, depending on individual lymphomas, either enhancement or suppression of spontaneous tumor cell DNA synthesis occurred after prolonged preincubation with anti-Id MoAb.
DISCUSSION
We have shown that in human B-cell lymphomas of different histologic types, anti-Id antibodies frequently Similar to models of tolerance induction>34 the inhibition of lymphoma cell DNA synthesis was a direct effect of surface IgM crosslinking and did not involve Fc receptor ligation, as evidenced by an equal inhibitory potential of complete MoAb to idiotype or p heavy chain and their F(ab')* fragments, respectively. Monovalent Fab' fragments had no effect.
In the study reported here, three of five randomly selected low malignancy human B-cell lymphomas were sensitive to inhibitory signaling by surface IgM. In humans, only a few similar cases have been described. Mongini et a1 reported two cases of hairy cell leukemia, a rare lymphoma subtype, and one CLL that were inhibited by anti-p, MOA^.",'^ In two of these tumors, only T-cell supernatant or B-cell growth factor (BCGF)-induced growth could be blocked by anti-A antibody. In addition, Baeker and Rothstein found inhibition of mitogen-induced proliferation in three of 24 tested lymphoma^?^ The tumors iqvestigated by us belonged to different frequently diagnosed subtypes of NHL, and proliferation was investigated in the absence of growth factors besides human or bovine serum. Our results indicate that both lymphomas of small lymphocytic and follicular center cell morphology are frequently sensitive to anti-IgM-mediated growth inhibition in vitro so that the majority of low-malignancy NHLs may receive negative signals by surface IgM. Differing from our data, most published studies have not described inhibitory effects of anti-IgM on low-malignancy lymphoma cell DNA synthesis but have focussed on the requirements for stimulation by anti-Ig. In a variable proportion of the tumors, proliferation could be induced by stimulation with a-p, antibody predominantly in combination with phorbol B-cell growth factor," or T-cell supernatant.' Thus, depending on the experimental system, both positive and negative effects of surface Ig crosslinking in B-cell lymphomas have been described, suggesting that factors such as the quantity of the signal and the presence of additional signals determine the outcome of surface Ig ligation in lymphomas.
Interestingly, our results are in contrast to the report of Lowder et al,I5 who investigated the in vitro proliferation of seven lymphomas, three of which had undergone a partial or complete clinical response to anti-Id treatment in vivo. Only one of these showed a reduction of 37% and 86% on days 5 and 7, respectively, when cultured in the presence of anti-Id MoAb. How does this fit in with our observation of inhibitory effect in the majority of the tumors?
Inhibition of DNA synthesis cannot be observed in the absence of a sufficient level of spontaneous 3H-thymidine incorporation, which was shown to be critically dependent on several variables in the cases reported. These variables comprised cell density and source and concentration of serum supplement. Thus, spontaneous DNA synthesis of most lymphomas in vitro is highly dependent on cell culture conditions, and under inappropriate conditions growth inhibition by anti-IgM reagents may well be overlooked. In the study by Lowder et al," tumor cells were cultured in 5% FCS at 1 x lo6 cells/mL. Among the five tumors studied here, only lymphoma LH would have proliferated under these conditions. Similarly, among the seven lymphomas investigated by Lowder et al, the only tumor with a significant spontaneous DNA synthesis could be inhibited by anti-Ig. This lymphoma underwent a major clinical response, suggesting that in vitro inhibition of DNA synthesis may correlate with in vivo tumor regression after anti-Id therapy.
None of the phenotypic variables tested in this study correlated significantly with tumor susceptibility to inhibition. These parameters included histologic subtype, surface IgM density, surface IgM to IgD ratio, and leukocyte antigen expression. First, both of the two resistant and two of the three susceptible tumors belonged to the small lymphocytic subtype. Second, the very low amounts of surface IgM that were found in both resistant lymphomas were detected in one of the susceptible tumors, too. Lowder et a1 found no correlation between surface Ig density and modulation on tumor cells and MoAb isotype or avidity and clinical responses. Third, a clearly predominant IgM expression as well as a roughly equal density of IgM and IgD (as assessed by a flow cytometric analysis) could be found in both groups. Finally, similar patterns of expression of differentiation antigens were displayed. While no phenotypic differences were detectable, resistant tumors constantly showed a lower rate of spontaneous thymidine incorporation in vitro. One might speculate that inhibition could not be observed in these lymphomas because the adequate conditions for significant spontaneous growth were not provided.
What is the significance of the observed inhibition of DNA synthesis for anti-Id MoAb treatment in Vivo? Only therapeutic trials including both lymphomas that have been characterized as resistant and susceptible to inhibition of thymidine incorporation by MoAb in vitro can answer this question conclusively. Some issues, hdwever, can be tested in vitro: can tumor cells recover from antilId-mediated growth arrest, and does incubation with abti-Id MoAb impair lymphoma cell viability? We performed lbng-term incubation assays for up to 1 week, thus mimicking in vivo therapies in which MoAb levels of more than 1 pg/mL were maintained for more than 2 weeks." Our data indicate that the biologic response of lymphomas to prolonged incubation with anti-Id MoAb may vary considerably. Tumor MZ may represent lymphomas in which prolonged anti-Id treatment does not affect or even enhances tumor cell For personal use only. on October 24, 2017. by guest www.bloodjournal.org From 136 survival so that the lymphomas resume increased growth Bfter cessation of anti-Id treatment, possibly resulting in clinical progression. This tumor thus seems to be different from CLL tumors that progressed to a prolymphocytic bistologic appearance and showed apoptosis in addition to inhibition of DNA synthesis when incubated with anti-p MoAb.) ' Other lymphomas, such as immunocytoma LH and, most significantly, centrocytic lymphoma PH, may not be able to recover spontaneously from negative signaling by anti-Id MoAb. As shown in tumor PH, even surface IgM-mediated signaling for a few hours can be sufficient for permanent arrest of DNA synthesis, and decreased tumor cell viability. It is tempting to speculate that the apoptosis that has been reported to occur in a high proportion of normal germinal VAN ENDERT ET AL center B cells3' could be induced by antigen or anti-Id in certain lymphomas such as PH that are related to germinal center cells in morphology. Taken together, our results indicate that anti-Id therapy could take advantage of the particular sensitivity of a majority of B-cell lymphomas to negative signaling by the antigen receptor. Further studies are needed to determine the frequency of sensitive lymphomas among tumors of different subtypes and to clarify the relationship between in vitro and in vivo responses to anti-Id treatment.
